

## RESULTS OF GENERAL MEETING

**Melbourne, Australia – 24 April 2025:** Percheron Therapeutics Limited (ASX:PER or “the Company”) is pleased to advise the results of today’s General Meeting of shareholders.

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, the results of the General Meeting are set out in the attached report and include a summary of the poll voting results by proxies on each resolution considered at the General Meeting.

All resolutions to be voted on at the meeting were decided on a poll.

More than 450 shareholders voted or directed a proxy in the meeting. Of these, over 90% voted in favour of retaining the current Board and against the directors nominated by Powerhouse Ventures Limited.

”We are immensely thankful to shareholders for their emphatic support,” commented Dr Charmaine Gittleston, Chair of the Board at Percheron. “It is now time to put these disputes behind us and focus our entire efforts on the vital task of restoring value for shareholders. The team has been working hard to this end over the past several months, and we look forward to sharing updates on progress.”

~ ENDS ~

---

### About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTCQB: PERCF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company’s lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor, which has been investigated in a range of inflammatory conditions, including multiple sclerosis and Duchenne muscular dystrophy. For more information, please contact [info@PercheronTx.com](mailto:info@PercheronTx.com).

*This announcement has been authorized for release to the Australian Securities Exchange by the Board of Directors.*

---

**Percheron Therapeutics Limited**  
**General Meeting**  
**Thursday, 24 April 2025**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Removal of current Director - Dr Charmaine Gittleson	Ordinary	165,987,954 28.02%	426,475,066 71.98%	0 0.00%	0	166,133,863 28.03% 41	426,475,066 71.97% 419	0 0	Not Carried	N/A
2. Removal of current Director - Dr James Garner	Ordinary	157,127,974 26.52%	435,335,046 73.48%	0 0.00%	0	157,273,883 26.54% 41	435,335,046 73.46% 419	0 0	Not Carried	N/A
3. Removal of current Director - Dr Ben Gill Price	Ordinary	168,487,954 28.44%	423,975,066 71.56%	0 0.00%	0	168,633,863 28.46% 42	423,975,066 71.54% 418	0 0	Not Carried	N/A
4. Appointment of new Director - Mr Doron Eldar	Ordinary	161,783,596 27.50%	426,475,066 72.50%	0 0.00%	4,204,358	161,929,505 27.52% 39	426,475,066 72.48% 419	4,204,358 2	Not Carried	N/A
5. Appointment of new Director - Mr Julian Chick	Ordinary	161,783,596 27.50%	426,475,066 72.50%	0 0.00%	4,204,358	161,929,505 27.52% 39	426,475,066 72.48% 419	4,204,358 2	Not Carried	N/A
6. Appointment of new Director - Mr Richard Hamersley	Ordinary	161,783,596 27.50%	426,475,066 72.50%	0 0.00%	4,204,358	161,929,505 27.52% 39	426,475,066 72.48% 419	4,204,358 2	Not Carried	N/A

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.